$TNGX insider trading
Over the last 12 months, Tango Therapeutics insiders reported no purchases and 17 sales totaling $18.2M across SEC Form 4 filings. 65% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $18.2M 17 events
- Events · 12m
- 17 Form 4 filings, grouped
- Insiders · 12m
- 4 distinct reporters
- 10b5-1 share
- 65% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 27,000 | $22.37 | $604K | -18.9% | plan |
| Aug 3, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 27,000 | $27.24 | $736K | -18.9% | plan · 2 tranches |
| Jul 1, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 27,000 | $29.59 | $799K | -18.9% | plan · 2 tranches |
| Jun 1, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 20,860 | $23.06 | $481K | -15.3% | plan |
| Jun 1, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 6,140 | $22.25 | $137K | -4.3% | plan |
| May 1, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 27,000 | $21.23 | $573K | -18.9% | plan · 2 tranches |
| Apr 15, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 38,460 | $25 | $962K | -25.5% | plan |
| Apr 1, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 27,000 | $21.2 | $572K | -19.3% | plan |
| Mar 25, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 12,000 | $20.11 | $241K | -9.6% | plan |
| Mar 5, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 20,251 | $15 | $304K | -15.2% | plan |
| Feb 25, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 54,345 | $12.77 | $694K | -29% | plan |
| Feb 3, 2026 | Beckman DaniellaChief Financial Officer · O | ▼ Sale | 10,317 | $12.26 | $127K | -5.3% | 2 tranches |
| Feb 3, 2026 | Weber BarbaraDirector, Executive Chair · O·D | ▼ Sale | 30,519 | $12.26 | $374K | -1.8% | 2 tranches |
| Feb 3, 2026 | Crystal AdamPresident, R&D · O | ▼ Sale | 18,452 | $12.26 | $226K | -9% | 2 tranches |
| Oct 23, 2025 | Third Rock Ventures IV, L.P.10% | ▼ Sale | 477,401 | $10.15 | $4.8M | -3.4% | — |
| Sep 25, 2025 | Third Rock Ventures IV, L.P.10% | ▼ Sale | 500,000 | $8.02 | $4.0M | -3.5% | — |
| Sep 16, 2025 | Third Rock Ventures IV, L.P.10% | ▼ Sale | 363,541 | $7.04 | $2.6M | -2.5% | — |
| Sep 8, 2025 | Third Rock Ventures IV, L.P.10% | ▼ Sale | 729,365 | $7 | $5.1M | -4.7% | 2 tranches |
| Aug 22, 2025 | Third Rock Ventures IV, L.P.10% | ▼ Sale | 302,194 | $7 | $2.1M | -1.9% | — |
| Aug 19, 2025 | Third Rock Ventures IV, L.P.10% | ▼ Sale | 1,100,000 | $7.01 | $7.7M | -6.5% | — |
Every $TNGX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Tango Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $TNGX feed.